Clinical Trial Update: Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated neoadjuvant bevacizumab plus docetaxel in high-risk prostate cancer patients undergoing radical prostatectomy. Enrollment completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Taxotere (docetaxel)

Snippet

Sponsor: Mary-Ellen Taplin, MD | Conditions: Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Status: COMPLETED | Results posted: 2013-12-25